Seetharama D Jois Selected Research

leucyl- alanyl- arginyl- leucyl- leucyl- threonine

11/2019

Synthesis, Characterization, and Evaluation of Near-IR Boron Dipyrromethene Bioconjugates for Labeling of Adenocarcinomas by Selectively Targeting the Epidermal Growth Factor Receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seetharama D Jois Research Topics

Disease

15	Neoplasms (Cancer) 01/2022 - 01/2016
5	Lung Neoplasms (Lung Cancer) 06/2020 - 09/2017
3	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2017
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
2	COVID-19 01/2022 - 10/2020
2	Adenocarcinoma of Lung 01/2022 - 01/2020
2	Carcinoma (Carcinomatosis) 01/2021 - 01/2017
2	Adenocarcinoma 01/2020 - 11/2019
2	Colonic Neoplasms (Colon Cancer) 11/2019 - 01/2019
1	Infections 10/2020
1	Hypercholesterolemia 01/2020
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Experimental Arthritis 11/2015
1	Autoimmune Diseases (Autoimmune Disease) 11/2015
1	Rheumatoid Arthritis 11/2015

Drug/Important Bio-Agent (IBA)

7	Peptides (Polypeptides)IBA 01/2022 - 01/2016
6	PeptidomimeticsIBA 01/2022 - 11/2015
4	ErbB Receptors (EGF Receptor)IBA 12/2021 - 11/2019
3	Proteins (Proteins, Gene)FDA Link 02/2021 - 11/2015
3	4,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene (BODIPY)IBA 01/2020 - 01/2017
3	compound 18IBA 01/2020 - 09/2017
2	Pharmaceutical PreparationsIBA 01/2022 - 10/2021
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2017
2	Tyrosine Kinase InhibitorsIBA 02/2021 - 01/2020
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2021 - 01/2020
1	Cell Surface ReceptorsIBA 01/2022
1	LigandsIBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	pyrazoloneIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Biological ProductsIBA 12/2021
1	QuinazolinonesIBA 12/2021
1	Liposomes (Liposome)IBA 10/2021
1	Growth Factor ReceptorsIBA 02/2021
1	AntibodiesIBA 02/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2021
1	Single-Domain AntibodiesIBA 02/2021
1	Cyclic PeptidesIBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 10/2020
1	Antiviral Agents (Antivirals)IBA 10/2020
1	Anti-HIV Agents (AIDS Drugs)IBA 10/2020
1	Nelfinavir (Viracept)FDA Link 10/2020
1	oleocanthalIBA 06/2020
1	Olive OilIBA 06/2020
1	Contrast MediaIBA 01/2020
1	LuciferasesIBA 01/2020
1	Epidermal Growth Factor (EGF)IBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	LDL Receptors (LDL Receptor)IBA 01/2020
1	Anaplastic Lymphoma KinaseIBA 01/2020
1	pseurotinIBA 01/2020
1	Hormones (Hormone)IBA 01/2020
1	leucyl- alanyl- arginyl- leucyl- leucyl- threonineIBA 11/2019
1	Adenosine (Adenocard)FDA LinkGeneric 01/2019
1	Codon (Codons)IBA 01/2019
1	RNA Precursors (Precursor, mRNA)IBA 01/2019
1	6-methyladenineIBA 01/2019
1	N-methyladenosineIBA 01/2019
1	MethyltransferasesIBA 01/2019
1	CeramidesIBA 01/2019
1	Mutant Proteins (Protein, Mutant)IBA 01/2019
1	Amino Acids FDA Link 02/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2017
1	AnthracyclinesIBA 01/2017
1	mesoporphyrin IXIBA 01/2016

Therapy/Procedure

4	Therapeutics 01/2020 - 09/2017
1	Precision Medicine 02/2021
1	Immunotherapy 01/2020
1	Intravenous Administration 11/2019
1	Immunomodulation 11/2015